Generation of affinity ranged antigen-expressing tumor cell lines

Area of Science:

• Immunology
• Cancer Biology
• T Cell Biology

Background:

• The strength of CD8+ T cell receptor (TCR) interaction with peptide-MHC (pMHC) is crucial for effective anti-pathogen and anti-tumor responses.
• Tumor-specific CD8+ T cell responses involve both low-affinity T cells recognizing self-antigens and high-affinity T cells recognizing mutated antigens.
• High-affinity T cells demonstrate superior tumor control, as evidenced by improved survival in clinical trials using neoantigen vaccines.

Purpose of the Study:

• To investigate strategies for enhancing the anti-tumor properties of TAA-specific CD8+ T cell responses.
• To identify high-affinity antigens and CD8+ T cells for designing effective cancer vaccines and adoptive cell transfer therapies.
• To describe methods for generating tumor cell lines with stable expression of affinity-ranged antigens and assessing T-cell affinity.

Main Methods:

• Generation of tumor cell lines engineered for stable expression of antigens across a range of affinities.
• Assessment of T-cell affinity using established immunological assays.
• Analysis of CD8+ T cell responses, including survival, expansion capacity, and tumor control.

Main Results:

• Tumor cell lines with controlled antigen expression were successfully generated.
• Methods for assessing T-cell affinity and response were established.
• Data suggests a correlation between T-cell affinity and anti-tumor efficacy.

Conclusions:

• Characterizing TAA-specific CD8+ T cell responses can inform strategies to boost anti-tumor immunity.
• Identifying high-affinity antigens is critical for developing potent cancer immunotherapies.
• The described methods provide a framework for studying T-cell affinity in the context of cancer immunology.